-Along with the promoters, marquee investors like Mr Ashish Kacholia, India Bridge Fund, Mrs. Monika Garware participate in the issue
Mumbai, 29 December 2023: Sanjivani Paranteral Limited (BSE: 531569), a leading pharmaceutical company specialising in the manufacturing and distribution of high-quality parenteral and oral solid products, approved issuance of 600,000 convertible warrants to promoter Mr. Ashwani Khemka priced at Rs 135.10 per warrant. The company also approved preferential allotment of 16,86,000 equity shares at Rs 135.10 per share, amounting to Rs 22.77 crores to non-promoter investors. Some of the marquee investors who participated in this issue include India Bridge Fund (India Equity Fund1), Mr. Ashish Kacholia, Mrs. Monika Garware, Mr. Anurag Jain, Ashika Global Securities Pvt. Ltd.
This issuance marks a defining moment for the company, setting the stage for continued expansion and our steadfast dedication to advancing our position as a leading force in the development of a cutting-edge manufacturing facility in collaboration with Hindustan Antibiotics Limited for the production of IV formulations and IV sets. A part of the funding will be allocated towards modernizing our existing facilities, reinforcing our infrastructure to meet the demands of progressive technology and industry standards.
Srivardhan Khemka, Director, Sanjivani Paranteral Ltd, said, “This capital infusion strengthens our collaboration with Hindustan Antibiotics Limited for IV formulations and emphasizes our unwavering focus on shareholder value and healthcare, empowering us to drive forward. With investor support, we’re poised for greater success and innovation.”
About Sanjivani Paranteral Limited:
Sanjivani Paranteral Limited is a pharmaceutical company headquartered in Mumbai, with manufacturing plants in Navi Mumbai and Dehradun. Operating in 25 countries, the company is 70% export-oriented and has more than 100 product approvals worldwide. It specializes in manufacturing and distributing high-quality parenteral and oral solid products, with a focus on therapeutic areas such as CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics, and Anti-Allergic, supported by a robust R&D setup.
Website: Sanjivani Paranteral Limited